Jie Shen: Yes, most of PS1 transgenic mice are made in the wild-type PS1 background, so in these mice, there is more PS1.
Keith Crutcher: This may be completely off the wall, but I wonder if this fascinating role of PS1 in neurogenesis might suggest that mutations actually result in a hypoproliferation such that Alzheimer disease (AD) patients are actually at risk due to fewer neurons to begin with?
Jie Shen: Keith, I think it is possible. That is the reason we are looking into the knock-in mice for this.
Keith Crutcher: Has anyone actually looked at PS1 brains prior to AD (I expect there are a few) to see if this might be the case? I have wondered about whether the conclusion that AD involves significant neuronal loss might actually be due to already fewer neurons in individuals at risk . . . a variant of the reserve hypothesis.
June Kinoshita: Keith, I have wondered the same thing myself. Jie, are there other approaches to gene silencing that might be applicable?
Jie Shen: June, the best approach is to have an inducible system selectively turn on and off genes in neural stem cells, but the problem is that there is no inducible system that is working as we would like, and there is no specific promoter, so we have to use other methods to get around these problems. June Kinoshita: There may be families with PS1 mutations who have elected to therapeutically abort a fetus . . . But that is such a delicate issue.
Keith Crutcher: Jie, are pre-AD PS1 mutant carriers characterized along other neurological dimensions? I do not know this literature.
June Kinoshita: There might be someone doing volumetric measurements of such individuals, but again, I do not know how many families are being genotyped at this time.
Jie Shen: I am not aware of any literature on that. I do not think people have focused on the issue.
June Kinoshita: I wonder if Drosophila or C. elegans might be a useful model system for addressing some of these questions. What do you think, Jie?
Jie Shen: These model systems are great to address the normal function, but I am not sure whether they are good systems for FAD mutations, due to sequence divergence.
June Kinoshita: Jie, can you explain? Are there significant differences between mammalian presenilins and their homologues in fly and worm?
Jie Shen: June, yes. I do not remember the exact number, around 50 percent.
Kiminobu Sugaya: I think AβPP production by PS mutation may also be important for stem cell differentiation or migration. We found sAβPP promotes glial differentiation of stem cells. Has anybody checked on this?
Jie Shen: Kiminobu, maybe. Unfortunately, we know so little of the in vivo function of AβPP and its family members in neural development. I wish someone would do what we are doing with presenilins to make double and triple cell type-specific conditional knockout to dissect out their specific function.
June Kinoshita: For your information, Gabriel Corfas at Children's Hospital, Boston, Massachusetts, is interested in the function of AβPP in neural development.
Jie Shen: Great, I should talk to him.
June Kinoshita: Regarding sequence divergence, that is intriguing in a gene that regulates progenitor cell proliferation. So, has it evolved in mammals to govern a function that is specific to mammalian brains?
Kiminobu Sugaya: Down's syndrome patient stem cells also mainly differentiated into glia rather than neurons.
Richard Bowen: I am sure many of you are aware of the work that has been done on AD and cell cycle. Mark Smith, among others, believes that neuronal death is due to aberrant entry of terminally differentiated neurons into the cell cycle [2] . Could it be that PS mutations are turning on the cell cycle in these terminally differentiated cells, resulting in dysfunction or apoptosis?
Jie Shen: PS in Drosophila may regulate cell cycle, too.
Richard Bowen: Down's syndrome patients also have much higher gonadotropin levels than does the general population. Jie, we are looking at how gonadotropins may affect the cell cycle. Since human chorionic gonadotropin hCG is extremely high during pregnancy, we are wondering if it might be affecting the presenilins.
Jie Shen: Richard, interesting.
Richard Bowen: Jie, does the PS mutation affect hormone levels in these animals?
Jie Shen: I do not know.
June Kinoshita: Jie, apropos of Richard's remark, do you have any thoughts about how presenilin might affect postmitotic neurons?
Richard Bowen: The tissue with the highest expression of PS is the testes, obviously a high rate of cell cycle there.
Kiminobu Sugaya:
We have not seen any increased apoptosis in previous PS1 mutant transgenic mice. June Kinoshita: Not to toot our own horn, but Inez Vincent put together a beautiful summary of the data on our site [3] .
Jie Shen: I guess, then, the evidence is indirect, since up-or downregulation of proteins involved in cell cycle does not necessarily mean cell cycle is affected.
Keith Crutcher: Yes; actually Mark Smith made this point [4] at the debate conference last summer, as well.
Kiminobu Sugaya: So the argument that PS1 changes a terminally differentiated neuron's cell cycle and causes neuronal cell death could be questionable.
Richard Bowen: Hiroko, Mark Smith is not the only one who has done work on this. I believe there are over 30 papers on the subject of AD and cell cycle abnormalities. I think that Karl Herrup has even shown that there is polyploidy in AD neurons, but not in control [5] . June, was there not a recent live discussion on the subject of cell cycle and AD?
